A Phase 1/2, Open-label, Multi-center, Initial Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Containing ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT 1)
This translation was generated automatically based on information in Dutch. It has not been reviewed by a medical specialist. The purpose of this translation is to make our information accessible to non-Dutch speakers. However, this information should not be considered a substitute for medical advice from your treating physician. The Netherlands Cancer Institute cannot guarantee the accuracy of this translation. For medical questions or advice, please consult your physician.
The NKI Centre for Early Clinical Studies places functional cookies and analytical cookies with very little or no privacy impact, unless you give permission for other cookies (as shown below). More information can be found in our cookie statement at the bottom of this page.
Cookie Information
Accept cookies!
nl